miR-3648 facilitates prostate cancer cell proliferation by inhibiting APC2, which leads to the activation of the Wnt/β-catenin pathway by increasing cyclin D1 and cyclin E1 expression and decreasing p21 expression [13]. Here, CCNE1 is linked to prostate carcinoma.